Log in

Relevant bibliographies by topics / Recombinant vaccine / Journal articles

To see the other types of publications on this topic, follow the link: Recombinant vaccine.

Journal articles on the topic 'Recombinant vaccine'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Recombinant vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jawad, J., R. W. Astuti, A. Haryanto, and N. Wijayanti. "Antibody response to Newcastle disease virus recombinant fusion protein in post-vaccinated laying hens." Journal of the Indonesian Tropical Animal Agriculture 48, no. 1 (2022): 20–27. http://dx.doi.org/10.14710/jitaa.48.1.20-27.

Full text

Abstract:

This research was aimed to analyze antibody response in laying hens post vaccinated by Newcastle Disease Virus (NDV) recombinat Fusion (F) protein which has been succesfully expressed from the F gene of local isolates of NDV from Kulon Progo strain (0663/04/2013), Yogyakarta, Indonesia. The F gene cloned into expression vector plasmid pBT7-N-His. Two types of NDV recombinant vaccine, a concentrated and pure F recombinant protein were used for vaccination. A concentrated recombinant F protein was collected from the centrifugal ultrafiltration process and a pure recombinant F protein was collect

APA, Harvard, Vancouver, ISO, and other styles

2

van Diepen, Michiel, Rosamund Chapman, Nicola Douglass, et al. "Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector." Vaccines 9, no. 10 (2021): 1131. http://dx.doi.org/10.3390/vaccines9101131.

Full text

Abstract:

Attenuated vaccine strains of lumpy skin disease virus (LSDV) have become increasingly popular as recombinant vaccine vectors, to target both LSDV, as well as other pathogens, including human infectious agents. Historically, these vaccine strains and recombinants were generated in primary (lamb) testis (LT) cells, Madin–Darby bovine kidney (MDBK) cells or in eggs. Growth in eggs is a laborious process, the use of primary cells has the potential to introduce pathogens and MDBK cells are known to harbor bovine viral diarrhea virus (BVDV). In this study, data is presented to show the growth of an

APA, Harvard, Vancouver, ISO, and other styles

3

Prayugo, Armanda Dwi, Toto Subroto, and Wyanda Arnafia. "Efficacy of Hemagglutinin Gene of Highly Pathogenic Avian Influenza as a Vaccine Candidate in Poultry: A Review." World's Veterinary Journal 13 (March 25, 2023): 26–31. http://dx.doi.org/10.54203/scil.2023.wvj3.

Full text

Abstract:

The most prevalent fatal disease in poultry that can result in high morbidity and mortality is highly pathogenic avian influenza (HPAI), subtype H5N1. A vaccination program is the most frequent way to prevent HPAI cases in poultry, especially against the H5 subtype of HPAI. There are currently a number of avian influenza vaccines available, including recombinant and inactivated whole virus vaccines. The foundation of a recombinant vaccine is possible by the expression of an avian influenza gene of interest following insertion into a carrier vector (no pathogenic virus). A recombinant HPAI vacc

APA, Harvard, Vancouver, ISO, and other styles

4

Marra, Yasmin, and Fawziah Lalji. "Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines." Viruses 14, no. 12 (2022): 2667. http://dx.doi.org/10.3390/v14122667.

Full text

Abstract:

Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be betw

APA, Harvard, Vancouver, ISO, and other styles

5

Ertl, H. C., and Z. Xiang. "Novel vaccine approaches." Journal of Immunology 156, no. 10 (1996): 3579–82. http://dx.doi.org/10.4049/jimmunol.156.10.3579.

Full text

Abstract:

Abstract Recent advances in immunology, molecular biology, and peptide biochemistry have allowed the construction of subunit vaccines based on viral or bacterial recombinants, peptides or plasmid vectors. Although none of these approaches is currently being used for mass vaccination (with the exception or vaccinia-rabies G protein recombinant virus for wildlife immunization); several of them are undergoing clinical trials. None of these different vaccine constructs is likely to be totally effective in either the prevention of infectious diseases or immunotherapy of cancer. Recombinant viral va

APA, Harvard, Vancouver, ISO, and other styles

6

Wu, Xiao-Xin, Hang-Ping Yao, Nan-Ping Wu, et al. "Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease." Cellular Physiology and Biochemistry 37, no. 5 (2015): 1641–58. http://dx.doi.org/10.1159/000438531.

Full text

Abstract:

Ebolaviruses are highly infectious pathogens that cause lethal Ebola virus disease (EVD) in humans and non-human primates (NHPs). Due to their high pathogenicity and transmissibility, as well as the potential to be misused as a bioterrorism agent, ebolaviruses would threaten the health of global populations if not controlled. In this review, we describe the origin and structure of ebolaviruses and the development of vaccines from the beginning of the 1980s, including conventional ebolavirus vaccines, DNA vaccines, Ebola virus-like particles (VLPs), vaccinia virus-based vaccines, Venezuelan equ

APA, Harvard, Vancouver, ISO, and other styles

7

Koeberling, Oliver, Isabel Delany, and Dan M. Granoff. "A Critical Threshold of Meningococcal Factor H Binding Protein Expression Is Required for Increased Breadth of Protective Antibodies Elicited by Native Outer Membrane Vesicle Vaccines." Clinical and Vaccine Immunology 18, no. 5 (2011): 736–42. http://dx.doi.org/10.1128/cvi.00542-10.

Full text

Abstract:

ABSTRACTNative outer membrane vesicles (NOMV) (not detergent treated), which are prepared from recombinant strains with attenuated endotoxin activity and overexpressed factor H binding protein (fHbp), elicited broad serum bactericidal antibody responses in mice. The amount of overexpressed fHbp required for optimal immunogenicity is not known. In this study we prepared NOMV vaccines from LpxL1 knockout (ΔLpxL1) mutants with penta-acylated lipooligosaccharide and attenuated endotoxin activity. The recombinant strains had wild-type (1×) fHbp expression or were engineered for 3-fold- or 10-fold-i

APA, Harvard, Vancouver, ISO, and other styles

8

Hudu, Shuaibu Abdullahi, Saadatu Haruna Shinkafi, and Shuaibu Umar. "AN OVERVIEW OF RECOMBINANT VACCINE TECHNOLOGY, ADJUVANTS AND VACCINE DELIVERY METHODS." International Journal of Pharmacy and Pharmaceutical Sciences 8, no. 11 (2016): 19. http://dx.doi.org/10.22159/ijpps.2016v8i11.14311.

Full text

Abstract:

Development of an effective vaccine is of paramount important in disease prevention and control. As such, recombinant technology can serve as a gateway for the development of safe and effective vaccines that can be delivered effectively with an appropriate adjuvant. Therefore, this paper aimed to review the role of recombinant vaccine technology, new adjuvants and the challenge of vaccine delivery. Related peer-reviewed journal article searches were conducted using a subscribed database at the Universiti Putra Malaysia library, involving areas of Health Sciences and Medicine via Medline, SCOPU

APA, Harvard, Vancouver, ISO, and other styles

9

Dewidar, Abdelmonem A. A., Walid H. Kilany, Azza A. El-Sawah, et al. "Genotype VII.1.1-Based Newcastle Disease Virus Vaccines Afford Better Protection against Field Isolates in Commercial Broiler Chickens." Animals 12, no. 13 (2022): 1696. http://dx.doi.org/10.3390/ani12131696.

Full text

Abstract:

This study evaluated the efficacy of live and inactivated conventional GII LaSota and recombinant GVII Newcastle disease vaccines in commercial broilers. The experimental groups (G2–G7) were vaccinated on day 7 and day 21 of age with live vaccines from the same vaccine type “GII LaSota, GVII vaccine (A), GVII vaccine (B)” via eye drop; however, G3, G5, and G7 received a single dose from inactivated counterpart vaccines subcutaneously on day 7 of age. Vaccine efficacy was evaluated based on elicited humoral immunity, clinical protection, and reduction in virus shedding after challenge with viru

APA, Harvard, Vancouver, ISO, and other styles

10

Baldo, Aline, Amaya Leunda, Nicolas Willemarck, and Katia Pauwels. "Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2." Vaccines 9, no. 5 (2021): 453. http://dx.doi.org/10.3390/vaccines9050453.

Full text

Abstract:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used for the development of COVID-19 vaccine candidates: recombinant viral vectors, protein-based vaccines, nucleic acid-based vaccines, and inactivated/attenuated virus. Recombinant viral vector vaccine candidates represent a significant part of those vaccine candidates in clinical development, with tw

APA, Harvard, Vancouver, ISO, and other styles

11

Park, Seong Yeon. "What is Different about Recombinant Herpes Zoster Vaccine?" Korean Journal of Medicine 99, no. 4 (2024): 180–88. http://dx.doi.org/10.3904/kjm.2024.99.4.180.

Full text

Abstract:

Herpes zoster (HZ) affects about one in three persons in their life time. Compared with the general population, older adults with immune senescence and individuals who are immunocompromised therapy are at increased risk for HZ, and its debilitating complications. To prevent HZ, two HZ vaccines, zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV) are available. RZV is The Korean Society of Infectious Diseases revised guidelines for HZ vaccine in 2023, and recommended to vaccinate with RZV for adults ≥ aged 50 years and for severely immunocompromised adults aged ≥ 18 years. RZV is mor

APA, Harvard, Vancouver, ISO, and other styles

12

Trujillo, Edgar, Abel Ramos-Vega, Elizabeth Monreal-Escalante, Consuelo Almazán, and Carlos Angulo. "Overview of Recombinant Tick Vaccines and Perspectives on the Use of Plant-Made Vaccines to Control Ticks of Veterinary Importance." Vaccines 12, no. 10 (2024): 1178. http://dx.doi.org/10.3390/vaccines12101178.

Full text

Abstract:

Ticks are obligate hematophagous ectoparasites that affect animals, and some of them transmit a wide range of pathogens including viruses, bacteria, and protozoa to both animals and humans. Several vaccines have shown immunogenicity and protective efficacy against ticks in animal models and definitive hosts. After several decades on anti-tick vaccine research, only a commercial vaccine based on a recombinant antigen is currently available. In this context, plants offer three decades of research and development on recombinant vaccine production to immunize hosts and as a delivery vehicle platfo

APA, Harvard, Vancouver, ISO, and other styles

13

Kumar, Vivek, Anuj Verma, Riddhi Singh, et al. "Recombinant vaccines: Current updates and future prospects." Asian Pacific Journal of Tropical Medicine 17, no. 8 (2024): 338–50. http://dx.doi.org/10.4103/apjtm.apjtm_854_23.

Full text

Abstract:

Recombinant technology-based vaccines have emerged as a highly effective way to prevent a wide range of illnesses. The technology improved vaccine manufacturing, rendering it more efficient and economical. These vaccines have multiple advantages compared to conventional vaccines. The pandemic has heightened awareness of the advantages of these vaccine technologies; trust and acceptance of these vaccines are steadily growing globally. This work offers an overview of the prospects and advantages associated with recombinant vaccines. Additionally, it discusses some of the challenges likely to ari

APA, Harvard, Vancouver, ISO, and other styles

14

Muravyova, N. V., and B. S. Belov. "Vaccination against Herpes zoster in patients with immune-mediated inflammatory rheumatic diseases: new data." Modern Rheumatology Journal 18, no. 4 (2024): 115–20. http://dx.doi.org/10.14412/1996-7012-2024-4-115-120.

Full text

Abstract:

Patients with immune-mediated inflammatory rheumatic diseases (IIRD) are more likely to develop herpes zoster (HZ) than individuals in the general population. Live attenuated vaccines and inactivated recombinant vaccines with adjuvant are available to prevent the disease and its complications. Live attenuated vaccine can be used in patients with IIRD if certain conditions are met, although these cannot always be fulfilled. The advantage of the inactivated recombinant adjuvant vaccine is that it can be used against a background of anti-rheumatic therapy. The review analyzes foreign studies on t

APA, Harvard, Vancouver, ISO, and other styles

15

Yan, Lin, Jin Qiu, Jianbo Chen, et al. "Selected prfA* Mutations in Recombinant Attenuated Listeria monocytogenes Strains Augment Expression of Foreign Immunogens and Enhance Vaccine-Elicited Humoral and Cellular Immune Responses." Infection and Immunity 76, no. 8 (2008): 3439–50. http://dx.doi.org/10.1128/iai.00245-08.

Full text

Abstract:

ABSTRACT While recombinant Listeria monocytogenes strains can be explored as vaccine candidates, it is important to develop attenuated but highly immunogenic L. monocytogenes vaccine vectors. Here, prfA* mutations selected on the basis of upregulated expression of L. monocytogenes PrfA-dependent genes and proteins were assessed to determine their abilities to augment expression of foreign immunogens in recombinant L. monocytogenes vectors and therefore enhance vaccine-elicited immune responses (a prfA* mutation is a mutation that results in constitutive overexpression of PrfA and PrfA-dependen

APA, Harvard, Vancouver, ISO, and other styles

16

Stovba, L. F., N. K. Chernikova, A. L. Khmelev, and S. V. Borisevich. "Anti-Vector Immune Response Formed after Immunization with Recombinant Vaccines Based on the Vaccinia Virus, MVA Strain." Problems of Particularly Dangerous Infections, no. 1 (April 7, 2025): 105–11. https://doi.org/10.21055/0370-1069-2025-1-105-111.

Full text

Abstract:

The search for safe approaches to primary immunization of the adult population under the absence of herd immunity to orthopoxviruses, when re-initiation of smallpox vaccination campaign is required, is currently very relevant. Thereat, the clinical trials of recombinant vaccines based on the vaccinia virus, MVA strain, against different illnesses confirm that they are safe for humans and in addition to target efficiency (capacity to induce immunity to proteins expressed by embedded foreign genes), show immunogenicity to vector – vaccinia virus. The aim of the review was to evaluate anti-vector

APA, Harvard, Vancouver, ISO, and other styles

17

Shollenberger, Lisa, Rafaella Grenfell, E. Farah Samli, and Donald Harn. "Vaccine self-assembling immune matrix (VacSIM) is a non-viral delivery platform that augments responses to recombinant protein vaccines (VAC6P.940)." Journal of Immunology 192, no. 1_Supplement (2014): 140.1. http://dx.doi.org/10.4049/jimmunol.192.supp.140.1.

Full text

Abstract:

Abstract Vaccination remains the most effective public health tool to prevent infectious disease. However, many vaccines remain marginally effective, especially for immune-compromised populations. To enhance vaccine immunogenicity, we exploited the biphasic property of certain synthetic oligopeptides to create a new vaccine delivery method, VacSIM (vaccine self-assembling immune matrix). Vaccine components are easily mixed with the VacSIM solution for injection, after which the peptides self-assemble into hydrated nanofiber gel-matrices, forming a vaccine depot. Thus, we have a non-viral, iner

APA, Harvard, Vancouver, ISO, and other styles

18

Hongying, Fan, Wu Xianbo, Yu Fang, Bai Yang, and Long Beiguo. "Oral Immunization with Recombinant Lactobacillus acidophilus Expressing the Adhesin Hp0410 of Helicobacter pylori Induces Mucosal and Systemic Immune Responses." Clinical and Vaccine Immunology 21, no. 2 (2013): 126–32. http://dx.doi.org/10.1128/cvi.00434-13.

Full text

Abstract:

ABSTRACTHelicobacter pyloriinfection is relatively common worldwide and is closely related to gastric mucosa-associated lymphoid tissue (MALT) lymphoma, chronic gastritis, and stomach ulcers. Therefore, a safe and effective method for preventingH. pyloriinfection is urgently needed. Given that developing an effective vaccine againstH. pyloriis one of the best alternatives,H. pyloriadhesin Hp0410 was expressed in the food-grade bacteriumLactobacillus acidophilus. The recombinant live bacterial vaccine was then used to orally vaccinate mice, and the immunoprotective effects of Hp0410-producing s

APA, Harvard, Vancouver, ISO, and other styles

19

Chang, Pengxiang, Faisal Ameen, Joshua E. Sealy, et al. "Application of HDR-CRISPR/Cas9 and Erythrocyte Binding for Rapid Generation of Recombinant Turkey Herpesvirus-Vectored Avian Influenza Virus Vaccines." Vaccines 7, no. 4 (2019): 192. http://dx.doi.org/10.3390/vaccines7040192.

Full text

Abstract:

Avian influenza viruses (AIVs) are highly contagious and have caused huge economical loss to the poultry industry. AIV vaccines remain one of the most effective methods of controlling this disease. Turkey herpesvirus (HVT) is a commonly used live attenuated vaccine against Marek’s disease; it has also been used as a viral vector for recombinant AIV vaccine development. The clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 system is a gene editing tool which, in vaccinology, has facilitated the development of recombinant DNA viral-vectored vaccines. Here, we utilize homology-dir

APA, Harvard, Vancouver, ISO, and other styles

20

McAllister, Andrés, Alejandra E. Arbetman, Stefanie Mandl, Claudia Peña-Rossi, and Raul Andino. "Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases." Journal of Virology 74, no. 19 (2000): 9197–205. http://dx.doi.org/10.1128/jvi.74.19.9197-9205.2000.

Full text

Abstract:

ABSTRACT We have genetically engineered an attenuated yellow fever (YF) virus to carry and express foreign antigenic sequences and evaluated the potential of this type of recombinant virus to serve as a safe and effective tumor vaccine. Live-attenuated YF vaccine is one of the most effective viral vaccines available today. Important advantages include its ability to induce long-lasting immunity, its safety, its affordability, and its documented efficacy. In this study, recombinant live-attenuated (strain 17D) YF viruses were constructed to express a cytotoxic T-lymphocyte epitope derived from

APA, Harvard, Vancouver, ISO, and other styles

21

Saito, Takeshi, Rachel A. Reyna, Satoshi Taniguchi, Kirsten Littlefield, Slobodan Paessler, and Junki Maruyama. "Vaccine Candidates against Arenavirus Infections." Vaccines 11, no. 3 (2023): 635. http://dx.doi.org/10.3390/vaccines11030635.

Full text

Abstract:

The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection ex

APA, Harvard, Vancouver, ISO, and other styles

22

DAČIĆ, M., R. RESANOVIC, Z. RASIC, M. VALCIC, A. MILOVANOVIC, and M. VELHNER. "Efficacy of recombinant VAXXITEK HVT-IBDv vaccine against very virulent Infectious bursal disease virus (vvIBDv) challenge in layer chicks: A pilot study." Journal of the Hellenic Veterinary Medical Society 69, no. 1 (2018): 823. http://dx.doi.org/10.12681/jhvms.16434.

Full text

Abstract:

The infectious bursal disease virus (IBDv) is widespread in poultry flocks all around the world. Various biotypes have emerged and because of that, adequate management practices and vaccination of chicks are of paramount importance for the protection against field strains. One day old Lohmann Brown chicks were vaccinated with intermediate vaccines and the recombinant VAXXITEK HVT-IBDv vaccine formulation, and challenged at 48 days of life with the very virulent IBDv (vvIBDv) strain CH/99. The best protection (100%) was achieved with the recombinant vaccine administered by the subcutaneous or i

APA, Harvard, Vancouver, ISO, and other styles

23

Pearl, Karlyn K., Ana A. Ortiz, and William Pearl. "Efficacy of Immunization with a Combination of Serum and Recombinant Hepatitis B Vaccines." Infection Control & Hospital Epidemiology 14, no. 8 (1993): 476–78. http://dx.doi.org/10.1086/646783.

Full text

Abstract:

AbstractObjective:To evaluate the efficacy of giving a third dose of recombinant hepatitis B vaccine to healthcare workers who already had received two doses of serum-derived vaccine, which is no longer available in the United States.Design:Volunteers who already had received two standard doses of serum-derived vaccine were given a third dose of either serum or recombinant vaccine in a double-blind fashion. Antibodies to hepatitis B surface antigen were measured at the time of the third immunization, three months later, and one year after the third immunization.Setting:U.S. Army Medical Center

APA, Harvard, Vancouver, ISO, and other styles

24

Levin, Myron J., Neda Al Rawashdh, Liliane Mofor, et al. "A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States." Vaccines 12, no. 11 (2024): 1217. http://dx.doi.org/10.3390/vaccines12111217.

Full text

Abstract:

Background: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives. Methods: A Susceptible–Exposed–Infectious–Recovered (SEIR) transmission model of the total US population followed with a cost-effectiveness model for 18–64-year-olds was used to estimate the clinical and economic impact of vaccination over one influenza season (2018–2019). Deterministic and probabilistic sensitivity analyses were conducted. Results: Both enhan

APA, Harvard, Vancouver, ISO, and other styles

25

Weaver, Eric A. "Dose Effects of Recombinant Adenovirus Immunization in Rodents." Vaccines 7, no. 4 (2019): 144. http://dx.doi.org/10.3390/vaccines7040144.

Full text

Abstract:

Recombinant adenovirus type 5 (rAd) has been used as a vaccine platform against many infectious diseases and has been shown to be an effective vaccine vector. The dose of the vaccine varies significantly from study to study, making it very difficult to compare immune responses and vaccine efficacy. This study determined the immune correlates induced by serial dilutions of rAd vaccines delivered intramuscularly (IM) and intranasally (IN) to mice and rats. When immunized IM, mice had substantially higher antibody responses at the higher vaccine doses, whereas, the IN immunized mice showed a lowe

APA, Harvard, Vancouver, ISO, and other styles

26

Berg, Michael G., Robert J. Adams, Ratish Gambhira, et al. "Immune Responses in Macaques to a Prototype Recombinant Adenovirus Live Oral Human Papillomavirus 16 Vaccine." Clinical and Vaccine Immunology 21, no. 9 (2014): 1224–31. http://dx.doi.org/10.1128/cvi.00197-14.

Full text

Abstract:

ABSTRACTImmunization with human papillomavirus (HPV) L1 virus-like particles (VLPs) prevents infection with HPV. However, the expense and logistical demands of current VLP vaccines will limit their widespread use in resource-limited settings, where most HPV-induced cervical cancer occurs. Live oral adenovirus vaccines have properties that are well-suited for use in such settings. We have described a live recombinant adenovirus vaccine prototype that produces abundant HPV16 L1 protein from the adenovirus major late transcriptional unit and directs the assembly of HPV16 VLPs in tissue culture. R

APA, Harvard, Vancouver, ISO, and other styles

27

Cuccui, Jon, Rebecca M. Thomas, Madeleine G. Moule, et al. "Exploitation of bacterial N -linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis." Open Biology 3, no. 5 (2013): 130002. http://dx.doi.org/10.1098/rsob.130002.

Full text

Abstract:

Glycoconjugate-based vaccines have proved to be effective at producing long-lasting protection against numerous pathogens. Here, we describe the application of bacterial protein glycan coupling technology (PGCT) to generate a novel recombinant glycoconjugate vaccine . We demonstrate the conjugation of the Francisella tularensis O-antigen to the Pseudomonas aeruginosa carrier protein exotoxin A using the Campylobacter jejuni PglB oligosaccharyltransferase . The resultant recombinant F. tularensis glycoconjugate vaccine is expressed in Escherichia coli where yields of 3 mg l −1 of culture were r

APA, Harvard, Vancouver, ISO, and other styles

28

Shahriari, Amir Ghaffar, and Maziar Habibi-Pirkoohi. "Plant-Based Recombinant Vaccine: Fact or Fiction?" Galen Medical Journal 6, no. 4 (2017): 268–80. http://dx.doi.org/10.31661/gmj.v6i4.792.

Full text

Abstract:

In the era of recombinant DNA technology, production of recombinant vaccines in green plants has emerged as an effective approach addressing the problems of traditional vaccine production. Various antigens expressed in different plant species have been so far tested for the production of efficient oral vaccines against human and livestock diseases. However, recombinant vaccines have not yet found a prominent place in pharmaceutical market. There are still many challenges to be addressed to pave the road for commercial production of plant-based recombinant vaccines. Regarding increasing growth

APA, Harvard, Vancouver, ISO, and other styles

29

Sarmadi, Mahdieh, Azam Gheibi, Hossein Khanahmad, et al. "Design and Characterization of a Recombinant Brucella abortus RB51 Vaccine That Elicits Enhanced T Cell-Mediated Immune Response." Vaccines 10, no. 3 (2022): 388. http://dx.doi.org/10.3390/vaccines10030388.

Full text

Abstract:

Brucella abortus vaccines help control bovine brucellosis. The RB51 strain is a live attenuated vaccine with low side effects compared with other live attenuated brucellosis vaccines, but it provides insufficient protective efficacy. Cell-mediated immune responses are critical in resistance against intracellular bacterial infections. Therefore, we hypothesized that the listeriolysin O (LLO) expression of Listeria monocytogenes, BAX, and SMAC apoptotic proteins in strain RB51 could enhance vaccine efficacy and safety. B. abortus RB51 was transformed separately with two broad-host-range plasmids

APA, Harvard, Vancouver, ISO, and other styles

30

Schlom, Jeffrey. "Recombinant cancer vaccines and new vaccine targets." Expert Review of Vaccines 12, no. 10 (2013): 1121–24. http://dx.doi.org/10.1586/14760584.2013.836913.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Stover, C. Kendall. "Recombinant vaccine delivery systems and encoded vaccines." Current Opinion in Immunology 6, no. 4 (1994): 568–71. http://dx.doi.org/10.1016/0952-7915(94)90143-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tang, Na, Yaoyao Zhang, Yashar Sadigh, et al. "Generation of A Triple Insert Live Avian Herpesvirus Vectored Vaccine Using CRISPR/Cas9-Based Gene Editing." Vaccines 8, no. 1 (2020): 97. http://dx.doi.org/10.3390/vaccines8010097.

Full text

Abstract:

Herpesvirus of turkeys (HVT), used originally as a vaccine against Marek’s disease (MD), has recently been shown to be a highly effective viral vector for generation of recombinant vaccines that deliver protective antigens of other avian pathogens. Until the recent launch of commercial HVT-vectored dual insert vaccines, most of the HVT-vectored vaccines in the market carry a single foreign gene and are usually developed with slow and less efficient conventional recombination methods. There is immense value in developing multivalent HVT-vectored vaccines capable of inducing simultaneous protect

APA, Harvard, Vancouver, ISO, and other styles

33

Barouch, Dan H., Paul F. McKay, Shawn M. Sumida, et al. "Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines." Journal of Virology 77, no. 16 (2003): 8729–35. http://dx.doi.org/10.1128/jvi.77.16.8729-8735.2003.

Full text

Abstract:

ABSTRACT Heterologous “prime-boost” regimens that involve priming with plasmid DNA vaccines and boosting with recombinant viral vectors have been shown to elicit potent virus-specific cytotoxic T-lymphocyte responses. Increasing evidence, however, suggests that the utility of recombinant viral vectors in human populations will be significantly limited by preexisting antivector immunity. Here we demonstrate that the coadministration of plasmid chemokines and colony-stimulating factors with plasmid DNA vaccines markedly increases the immunogenicity of DNA prime-recombinant adenovirus serotype 5

APA, Harvard, Vancouver, ISO, and other styles

34

Kumar, Pawan, Tamer A. Sharafeldin, Rahul Kumar, et al. "Development of a Recombinant Pichinde Virus-Vectored Vaccine against Turkey Arthritis Reovirus and Its Immunological Response Characterization in Vaccinated Animals." Pathogens 10, no. 2 (2021): 197. http://dx.doi.org/10.3390/pathogens10020197.

Full text

Abstract:

Vaccination may be an effective way to reduce turkey arthritis reovirus (TARV)-induced lameness in turkey flocks. However, there are currently no commercial vaccines available against TARV infection. Here, we describe the use of reverse genetics technology to generate a recombinant Pichinde virus (PICV) that expresses the Sigma C and/or Sigma B proteins of TARV as antigens. Nine recombinant PICV-based TARV vaccines were developed carrying the wild-type S1 (Sigma C) and/or S3 (Sigma B) genes from three different TARV strains. In addition, three recombinant PICV-based TARV vaccines were produced

APA, Harvard, Vancouver, ISO, and other styles

35

Pastoret, P. P., D. Boulanger, and B. Brochier. "Field trials of a recombinant rabies vaccine." Parasitology 110, S1 (1995): S37—S42. http://dx.doi.org/10.1017/s0031182000001475.

Full text

Abstract:

SummaryTo improve both safety and stability of the vaccines used in the field to vaccinate foxes against rabies by the oral route, a recombinant vaccinia virus, expressing the glycoprotein of rabies virus (VVTGgRAB) has been developed. VVTGgRAB innocuity was verified in target species and in domestic animals as well as in numerous wild animal species that could compete with the red fox in consuming vaccine baits in Europe. Oral immunization of foxes, by distributing VVTGgRAB vaccine-baits, was undertaken for the whole infected area in Belgium (10000 km2). Five campaigns of fox vaccination, wer

APA, Harvard, Vancouver, ISO, and other styles

36

Temchura, Vladimir, Jannik T. Wagner, and Dominik Damm. "Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand." Pharmaceutics 16, no. 1 (2023): 24. http://dx.doi.org/10.3390/pharmaceutics16010024.

Full text

Abstract:

Infectious diseases are a predominant problem in human health. While the incidence of many pathogenic infections is controlled by vaccines, some pathogens still pose a challenging task for vaccine researchers. In order to face these challenges, the field of vaccine development has changed tremendously over the last few years. For non-replicating recombinant antigens, novel vaccine delivery systems that attempt to increase the immunogenicity by mimicking structural properties of pathogens are already approved for clinical applications. Lipid-based nanoparticles (LbNPs) of different natures are

APA, Harvard, Vancouver, ISO, and other styles

37

Rizqoh, Debie. "Genetic Engineering Technique in Virus-Like Particle Vaccine Construction." Jurnal Kesehatan Masyarakat Indonesia 16, no. 4 (2021): 203. http://dx.doi.org/10.26714/jkmi.16.4.2021.203-211.

Full text

Abstract:

Vaccine becomes a very effective strategy to deal with various infectious diseases even to the point of eradication as in the smalpox virus. At present many conventional vaccines such as inactivated and live-attenuated vaccines. However, these vaccine methods have side effects on the population. Viral-like particle (VLP) is an alternative vaccine based on recombinant DNA technology that is safe with the same immunogenicity as conventional viruses. This vaccine has been shown to induce humoral immune responses mediated by antibodies and cellular immune responses mediated by cytotoxic T cells. W

APA, Harvard, Vancouver, ISO, and other styles

38

Ourmanov, Ilnour, Charles R. Brown, Bernard Moss, et al. "Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV." Journal of Virology 74, no. 6 (2000): 2740–51. http://dx.doi.org/10.1128/jvi.74.6.2740-2751.2000.

Full text

Abstract:

ABSTRACT Prior studies demonstrated that immunization of macaques with simian immunodeficiency virus (SIV) Gag-Pol and Env recombinants of the attenuated poxvirus modified vaccinia virus Ankara (MVA) provided protection from high levels of viremia and AIDS following challenge with a pathogenic strain of SIV (V. M. Hirsch et al., J. Virol. 70:3741–3752, 1996). This MVA-SIV recombinant expressed relatively low levels of the Gag-Pol portion of the vaccine. To optimize protection, second-generation recombinant MVAs that expressed high levels of either Gag-Pol (MVA-gag-pol) or Env (MVA-env), alone

APA, Harvard, Vancouver, ISO, and other styles

39

Willadsen, P., P. Bird, G. S. Cobon, and J. Hungerford. "Commercialisation of a recombinant vaccine againstBoophilus microplus." Parasitology 110, S1 (1995): S43—S50. http://dx.doi.org/10.1017/s0031182000001487.

Full text

Abstract:

SummaryIncreasingly, there is need for methods to control cattle tick (Boophilus microplus) infestations by the use of non-chemical technology. This need is brought about by a mixture of market forces and the failure or inadequacy of existing technology. A recombinant vaccine has now been developed against the tick. This vaccine relies on the uptake with the blood meal of antibody directed against a critical protein in the tick gut. The isolation of the vaccine antigen, Bm86, and its production as a recombinant protein is briefly described. The vaccine has been tested in the field, has been ta

APA, Harvard, Vancouver, ISO, and other styles

40

Tseng, Ta-Yuan, Yee-Chen Liu, Yu-Chen Hsu, et al. "Preparation of Chicken Anemia Virus (CAV) Virus-Like Particles and Chicken Interleukin-12 for Vaccine Development Using a Baculovirus Expression System." Pathogens 8, no. 4 (2019): 262. http://dx.doi.org/10.3390/pathogens8040262.

Full text

Abstract:

Chicken infectious anemia (CIA) is a poultry disease that causes huge economic losses in the poultry industry worldwide. Commercially available CIA vaccines are derived from wild-type chicken anemia viruses (CAVs) by serial passage in cells or chicken embryos. However, these vaccinal viruses are not completely attenuated; therefore, they can be transmitted vertically and horizontally, and may induce clinical symptoms in young birds. In this study, we sought to eliminate these issues by developing a subunit vaccine exploiting the CAV structural proteins, engineering recombinant baculovirus-infe

APA, Harvard, Vancouver, ISO, and other styles

41

Ma, Haoyuan, Haowen Xue, Jingfeng Fu, Yanhao Song, Kunru Zhu, and Xu Gao. "Recombination of Goose Parvovirus VP3 Gene and Goose Interferon Ɣ Gene from Fowlpox Virus Immune Protection and Its Mechanism." BIO Web of Conferences 60 (2023): 01010. http://dx.doi.org/10.1051/bioconf/20236001010.

Full text

Abstract:

Gosling plague (GP) is caused by goose parvovirus (GPV) gosling acute, subacute, and septic infectious diseases, commonly known as gosling plague. At present, the prevention and control of GP at home and abroad mainly adopts the method of immunizing female geese with attenuated vaccine. Goslings can be immunized, but there are still the phenomenon of dispersive virus and virulence reverse. It, therefore, is urgent to develop a new safe and effective vaccine. The recombinant avian pox virus vaccines rFPV-GoIFNγ, rFPV-GPV-VP3 and rFPV-GoIFNγ-VP3 were used to monitor their antibody levels and eva

APA, Harvard, Vancouver, ISO, and other styles

42

Rezende, A. F. S., A. A. Brum, F. S. B. Bezerra, et al. "Assessment of the acid phosphatase CP01850 from Corynebacterium pseudotuberculosis in DNA and subunit vaccine formulations against caseous lymphadenitis." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 72, no. 1 (2020): 199–207. http://dx.doi.org/10.1590/1678-4162-10790.

Full text

Abstract:

ABSTRACT The target cp1002_RS01850 from Corynebacterium pseudotuberculosis was used to construct a DNA and recombinant subunit vaccine against caseous lymphadenitis. Recombinant protein rCP01850 was expressed in Escherichia coli using pAE vector, and DNA vaccine was engineered with pTARGET vector. BALB/c mice were divided in five groups containing eight animals each, inoculated with: pTARGET/cp01850 as DNA vaccine (G1); rCP01850 plus Al (OH)3 as recombinant subunit vaccine (G2); pTARGET/cp01850 and a boost with rCP01850 plus Al (OH)3 (G3); pTARGET (G4); or Al (OH)3 (G5). Mice were inoculated a

APA, Harvard, Vancouver, ISO, and other styles

43

Yousefi, A., Fatemeh Fotouhi, S. Hosseinzadeh, et al. "Expression of Antigenic Determinants of the Haemagglutinin Large Subunit of Novel Influenza Virus in Insect Cells." Folia Biologica 58, no. 4 (2012): 151–56. http://dx.doi.org/10.14712/fb2012058040151.

Full text

Abstract:

The global outbreak of novel A/H1N1 spread in human population worldwide has revealed an emergency need for producing a vaccine against this virus. Current influenza vaccines encounter problems with safety issues and weak response in high-risk population. It has been established that haemagglutinin is the most important viral antigen to which antibody responses are directed, and recombinant subunit vaccines, haemagglutinin of influenza A and B viruses, have been considered in order to facilitate vaccine production. In the present study, we have focused on construction of a recombinant baculovi

APA, Harvard, Vancouver, ISO, and other styles

44

Zhang, Haiyan, Arun Sridhar, Natacha Delrez, et al. "Development Using Bioluminescence Imaging of a Recombinant Anguillid Herpesvirus 1 Vaccine Candidate Associated with Normal Replication In Vitro but Abortive Infection In Vivo." Vaccines 12, no. 12 (2024): 1423. https://doi.org/10.3390/vaccines12121423.

Full text

Abstract:

Background/Objectives: Anguillid herpesvirus 1 (AngHV-1) (recently renamed Cyvirus anguillidallo 1) is the etiologic agent of a lethal disease that affects several eel species. It is thought to be one of the main infectious agents causing a population decline in wild eels and economic loss within the eel aquaculture sector. To date, no vaccines are available against AngHV-1. Recently, we developed a safe and efficacious live attenuated recombinant vaccine against Cyprinid herpesvirus 3 (CyHV-3). This CyHV-3 recombinant vaccine encodes a deletion of ORF57. Orthologues of CyHV-3 ORF57 exist in C

APA, Harvard, Vancouver, ISO, and other styles

45

Shehata, Mahmoud M., Ahmed Kandeil, Ahmed Mostafa, et al. "A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice." Pathogens 8, no. 4 (2019): 281. http://dx.doi.org/10.3390/pathogens8040281.

Full text

Abstract:

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) became a global human health threat since its first documentation in humans in 2012. An efficient vaccine for the prophylaxis of humans in hotspots of the infection (e.g., Saudi Arabia) is necessary but no commercial vaccines are yet approved. In this study, a chimeric DNA construct was designed to encode an influenza A/H1N1 NA protein which is flanking immunogenic amino acids (aa) 736–761 of MERS-CoV spike protein. Using the generated chimeric construct, a novel recombinant vaccine strain against pandemic influenza A virus (H1N1pdm09) an

APA, Harvard, Vancouver, ISO, and other styles

46

Payton, C. D., D. A. Scarisbrick, S. Sikotra, and A. J. E. Flower. "Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines." Epidemiology and Infection 110, no. 1 (1993): 177–80. http://dx.doi.org/10.1017/s0950268800050792.

Full text

Abstract:

SUMMARYA retrospective analysis of levels of antibody to hepatitis B surface antigen in 1419 health care workers was carried out to compare the efficacy of intramuscular and intradermal administration of plasma derived and recombinant hepatitis B vaccines. No significant difference was detected between the response to intradermal and intramuscular plasma derived vaccine. However of those who received intramuscular recombinant vaccine 81.6%, 13.8% and 4.7% were good (> 100 miu/ml). low (10–99 miu/ml) and non-responders (< 10 miu/ml) respectively. compared with 51.1%, 29.8% and 19.2% of th

APA, Harvard, Vancouver, ISO, and other styles

47

KOŠOROK, Stane, and Miran KASTELIC. "Antibody response following sow vaccination using cell and recombinant vaccines, single and multiple application." Acta agriculturae Slovenica, no. 2 (September 15, 2008): 167–71. http://dx.doi.org/10.14720/aas-s.2008.2.19243.

Full text

Abstract:

The vaccination of pregnant sows with E. coli antigens to increase specific antibodies in colostrum and milk and subsequently the protection of suckling piglets from neonatal E. coli diarrhea is a common and efficient method, already used for many years. The vaccination to protect individual animals against erysipelas has been used even for a longer time. There are many vaccines and vaccination techniques available on the market, among them herd specific “stable” vaccines for E. coli, inactivated cell vaccines and recombinant DNA vaccines. Unlike vaccines for pet animals, which are mostly poly

APA, Harvard, Vancouver, ISO, and other styles

48

Cuervo, Nancy Stella, Sophie Guillot, Natalia Romanenkova, et al. "Genomic Features of Intertypic Recombinant Sabin Poliovirus Strains Excreted by Primary Vaccinees." Journal of Virology 75, no. 13 (2001): 5740–51. http://dx.doi.org/10.1128/jvi.75.13.5740-5751.2001.

Full text

Abstract:

ABSTRACT The trivalent oral poliomyelitis vaccine (OPV) contains three different poliovirus serotypes. It use therefore creates particularly favorable conditions for mixed infection of gut cells, and indeed intertypic vaccine-derived recombinants (VdRec) have been frequently found in patients with vaccine-associated paralytic poliomyelitis. Nevertheless, there have not been extensive searches for VdRec in healthy vaccinees following immunization with OPV. To determine the incidence of VdRec and their excretion kinetics in primary vaccinees, and to establish the general genomic features of the

APA, Harvard, Vancouver, ISO, and other styles

49

Zhang, Guihua, Yang Fu, Yu’an Li, Quan Li, Shifeng Wang, and Huoying Shi. "Oral Immunization with Attenuated Salmonella Choleraesuis Expressing the FedF Antigens Protects Mice against the Shiga-Toxin-Producing Escherichia coli Challenge." Biomolecules 13, no. 12 (2023): 1726. http://dx.doi.org/10.3390/biom13121726.

Full text

Abstract:

Edema disease (ED) is a severe and lethal infectious ailment in swine, stemming from Shiga-toxin-producing Escherichia coli (STEC). An efficient, user-friendly, and safe vaccine against ED is urgently required to improve animal welfare and decrease antibiotic consumption. Recombinant attenuated Salmonella vaccines (RASV) administered orally induce both humoral and mucosal immune responses to the immunizing antigen. Their potential for inducing protective immunity against ED is significant through the delivery of STEC antigens. rSC0016 represents an enhanced recombinant attenuated vaccine vecto

APA, Harvard, Vancouver, ISO, and other styles

50

Husseiny, Mohamed I., and Michael Hensel. "Rapid Method for the Construction of Salmonella enterica Serovar Typhimurium Vaccine Carrier Strains." Infection and Immunity 73, no. 3 (2005): 1598–605. http://dx.doi.org/10.1128/iai.73.3.1598-1605.2005.

Full text

Abstract:

ABSTRACT Salmonella enterica serovar Typhimurium is a versatile organism for the generation of live recombinant vaccines for mucosal immunization. Various strategies have been devised for the stable and efficient expression of heterologous antigens by attenuated S. enterica strains, but these methods often require complex manipulations. Use of phage λ Red recombinase has recently been devised for gene replacements in Escherichia coli and S. enterica after introduction of PCR products. Based on this method, we have developed an approach that allows the integration of recombinant expression cass

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!